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Diacerein is used for symptomatic relief and cartilage regeneration in osteoarthritis. Due to gastrointestinal 
side effects, poor aqueous solubility and low bioavailability, its clinical usage has been restricted. The 
objective of the present study was to enhance its dissolution profile and to attain sustained release by 
designing a novel delivery system based on niosomes. Five niosomal formulations (F1-F5) with non-
ionic surfactant (sorbitan monostearate) and cholesterol in varying ratios of 5:5, 6:4, 7:3, 8:2 and 9:1 
were developed by the reverse-phase evaporation technique. The size and polydispersivity index (PDI) 
were found in the range of 0.608 µm to 1.010 µm and 0.409 to 0.781, respectively. Scanning electron 
microscopy (SEM) of the selected formulation (F3) revealed spherical vesicles, and 79.8% entrapment 
was achieved with F3 (7:3). Dissolution studies using the dialysis method showed sustained release 
behaviour for all formulations. The optimized surfactant-to-cholesterol concentration (7:3) in formulation 
F3 sustained the drug-release time (T50%) up to 10 hours. Kinetic modelling exhibited a zero-order release 
(R2=0.9834) and the release exponent ‘n’ of the Korsmayer-Peppas model (n=0.90) confirmed non-fickian 
and anomalous release. The results of this study suggest that diacerein can be successfully entrapped into 
niosomes using sorbitan monostearate and that these niosomes have the potential to deliver diacerein 
efficiently at the absorption site.
Uniterms: Chondroprotective. Diacerein/dissolution profile. Diacerein/sustained release. Niosomes. 
Sorbitan monostearate. Reverse-phase evaporation.
A diacereína é usada para o alívio sintomático e para a regeneração da cartilagem na osteoartrite. Devido 
aos efeitos adversos gastrointestinais, baixa solubilidade aquosa e biodisponibilidade, o seu uso clínico 
tem sido restrito. O objetivo do presente estudo foi melhorar o perfil de dissolução deste fármaco e obter 
liberação prolongada através do planejamento de um novo sistema de liberação designado de niossoma. 
Cinco formulações distintas de niossomas (F1 a F5) contendo tensoativos não iônicos (monoestearato 
de sorbitano) e colesterol, em diferentes proporções, de 5:5, 6:4, 7:3, 8:2 e 9:1, foram desenvolvidas 
através da técnica de evaporacão de fase reversa. Os tamanhos e índices de polidispersibilidade (PDI) 
obtidos variam entre 0,608 e 1,01 µm e entre 0,409 e 0,7781, respectivamente. Imagens de microscopia 
electrônica de varrimento (SEM) da formulação selecionada (F3) revelaram vesículas esféricas. Obteve-se 
encapsulação de 79,8% com a formulação F3 (7:3). Estudos de dissolução usando o método de diálise 
demonstraram padrão de liberacão prolongada para todas as formulações. A proporção de tensoativo 
e colesterol (7:3) na formulacão F3 prolongou o tempo de liberação do fármaco (T50%) até 10 horas. 
Estudos de modelação cinética demonstraram ordem de liberacão zero (R2=0,9834) e o expoente de 
liberação “n” do modelo de Korsmayer-Peppas (n=0.90) confirmou a liberação não-fickiana e anômala. 
Os resultados deste estudo sugerem que a diacereína pode ser encapsulada com sucesso no interior de 
niossomas, utilizando monostearato de sorbitano, o qual tem potencial para liberar, eficientemente, a 
diacereína no local de absorção.
Unitermos: Condroprotetor. Diacereína/perfil de dissolução. Diacereína/liberação prolongada. 
Niossomas. Monoestearato de sorbitano. Evaporação em fase reversa.
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INTRODUCTION
Vesicular systems, including liposomes and 
niosomes, are spherical configurations comprised of 
amphiphiles assembled into unilamellar or multilamellar 
structures. They are considered as cell-like bioreactors 
or primitive cell models and as suitable candidates 
for biomaterial encapsulation. Niosomes have prime 
importance in drug delivery as they can reduce toxicity, 
alter pharmacokinetics, enhance bioavailability and also 
sustain the release of the drug (Muzzalupo et al., 2008).
In the 1970s, niosomes were considered as a part 
of the cosmetic industry. The self-assembled nature of 
nonionic surfactants in an aqueous medium leads to 
the formation of a close concentric bilayer structural 
configuration, similar to that of liposomes but without 
phospholipids (Waddad et al., 2013). Niosomes have the 
ability to encapsulate hydrophilic drug moieties in the 
inner aqueous core and hydrophobic drugs into the bilayer 
structure (Hong et al., 2009). Niosomes have better stability, 
more convenient handling and storage conditions and are 
more cost effective than liposomes. These characteristics 
have attracted much attention in the field of drug delivery 
(Marianecci et al., 2012). Sorbitan fatty acid esters, alkyl 
ethers, alkyl glyceryl ethers and polyoxyethylene (4) lauryl 
ether (Brij 30) are extensively employed components of 
niosomal formulations (Mahale et al., 2012).
Osteoarthritis is a degenerating disease of tissues and 
cartilage that causes changes in biochemical properties of 
synovial fluid due to breakdown in joints by local protease 
enzymes (Pearle, Warren, Rodeo, 2005). Metabolic, 
developmental, traumatic and genetic diseases may elicit 
osteoarthritis and alter the functionality of particular joints, 
such as the spine, hands, hip and knee (Shari, Bathon, 
2012). Diacerein is a new anthraquinone derivative that 
has analgesic and anti-inflammatory properties (Hunter, 
Wise, 2007). Clinical investigations have demonstrated 
that diacerein is an effective drug for the symptomatic 
relief of osteoarthritis (Nguyen et al., 1994). Diacerein 
is sparingly soluble in water (less than 0.01 mg/ml) 
(Maski et al., 2009). Several formulation strategies have 
been employed to produce diacerein with an improved 
dissolution and hence bioavailability profile. Diacerein 
was complexed with PEG 6000 in solid dispersions 
and there was a marked improvement in its dissolution 
rate and solubility (Aggarwal, Singh, 2011). An attempt 
was made to encapsulate diacerein into solid lipid 
nanoparticles by modified high-shear homogenization 
using an ultrasonication technique and stearic acid as 
the main constituting agent. Stearic acid-based solid 
lipid nanoparticles were found to be promising carriers 
for diacerein (Jain et al., 2013). Polyvinyl pyrrollidone 
K30 (PVP-K30) and hydroxypropyl methylcellulose E4 
(HPMC E4) have been employed to produce diacerein 
in a solid dispersion form to improve its solubility and 
dissolution rate (Deshmukh et al., 2010).
Limited data is available for the development of 
niosomal delivery systems for this chondroprotective 
agent. Therefore, the present study aimed to prepare a 
niosomal system to improve the solubility and thereby the 
bioavailability of diacerein by entrapping the drug in the 
vesicles of these systems. The added benefits are the low 
cost of formulation ingredients, easily operated methods, 
cost effectiveness, enhanced entrapment and retarded 
release of the drug.
MATERIAL AND METHODS
Material
Diacerein was received as a research material 
donation from Consolidated Chemical Laboratories 
(Pvt.) Ltd. Pakistan. Span 60 and cholesterol were 
purchased from Sigma Aldrich, UK. All solvents including 
ethanol (Sigma Aldrich), diethyl ether (Sigma Aldrich) 
and methanol were of HPLC grade (Sigma Aldrich). 
Distilled water was prepared fresh in the laboratory using 
distillation apparatus (Hamilton, England).
Preparation of niosomes
The niosomes were prepared using a reverse-phase 
evaporation method. The mixtures of surfactant and 
cholesterol in different molar ratios (5:5, 6:4, 7:3, 8:2, 
9:1) were accurately weighed (Table I) and dissolved in 
20 mL of chloroform/ethanol mixture (2:1 v/v) separately. 
The organic solvents from all formulations were slowly 
evaporated under reduced pressure in a rotary evaporator 
(Heidolph, Germany) at 60 oC until a smooth film of lipid 
components was formed on the wall of the rotating flask. 
The film was resuspended in 20 mL of ether. The drug 
solution (1 mg/mL) was prepared in a 15-mL mixture (2:1) 
of phosphate-buffered saline (PBS; pH 7.4) and ethanol. The 
mixture of lipid solution and drug solution was sonicated 
for 5 minutes and swirled by hand and then sonicated again 
for 2 minutes in a bath sonicator. The resulting dispersion 
was immediately evaporated to disrupt the formed gel. 
Then, 10 ml of PBS (pH 7.4) was added to the rotating flask 
and the evaporation was continued for 15 minute to ensure 
the complete removal of the remaining diethyl ether. The 
niosomal suspension was refrigerated at 4 oC overnight to 
obtain the mature vesicles (Guinedi et al., 2005).
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Characterization of vesicles
The developed niosomal formulations of diacerein 
with different molar ratios of Span 60 and cholesterol were 
characterized for vesicle size, morphology, polydispersity 
index (PDI) and entrapment efficiency.
Fourier transform infrared (FTIR) spectroscopic 
studies
The compatibility of the drug and other formulation 
components were studied using FTIR (Bruker FTIR, 
Tensor 27Series, Germany). Spectra of individual 
niosomal components and formulations were measured 
using a pike single-bounce attenuated total reflectance 
(ATR) cell equipped with a ZnSe single crystal. For solid 
samples (pure drug, cholesterol), samples were added to 
the ATR cell and measured directly. For liquids (niosomal 
formulation), samples were placed directly on the small 
crystal spot and lever having concave surface is placed 
over it in order to prevent evaporation.
Drug entrapment studies
Diacerein-loaded niosomal formulations were 
ultracentrifuged at 14,800 × g for 1.5 h to separate the 
unentrapped drug from the niosomes. The concentration of 
free drug in the supernatant was estimated by measuring the 
absorbance at 258.50 nm using a UV spectrophotometer 
(IRMECO U2020, Germany). This process was repeated 
to ensure complete removal of the free drug. The amount 
of entrapped drug was determined by mathematical 
equation (1), as described elsewhere (Alsarra et al., 2005):
Total drug – Drug in supernatant
% Drug entrapment × 100
Total drug
−
=  (1)
Morphological study
The morphological characteristics of niosomes 
were investigated using a field emission scanning 
electron microscope (JSM-7500F, Jeol, Japan). A drop of 
optimized niosomal formulation (F3) was mounted on an 
aluminium stub with adhesive silver tape. The stubs were 
stored overnight under a vacuum and then sputter-coated 
using gold.
Size and distribution measurements
Size and polydispersivity index were measured by 
a dynamic light-scattering technique using a Zetasizer 
(ZS-90 Malvern Instruments, UK). For the measurements, 
vesicle dispersions were diluted 100 times with the 
same PBS (pH 7.4) used for their preparation to avoid 
multiscattering of light. Buffer solutions were filtered 
through 0.45-μm cellulose filters to remove impurities. 
Vesicle mean size and size distribution (PDI) were 
determined at 25 °C while keeping the scattering angle at 
90°. The instrument was operated at medium refractive 
index 1.330, a medium viscosity of 1.0 mPa.s and 
dielectric constant of 80.4. Sample mean size and PDI 
were measured using the third-order cumulant fitting 
autocorrelation function.
Assessment of stability
The ability of niosomes to retain the drug was 
assessed by storing the niosomal formulations at two 
different temperatures, i.e. refrigeration temperature 
(4-8 oC) and ambient temperature (25oC ± 2 oC). Samples 
were stored in glass vials for 3 months and were withdrawn 
at regular time intervals. The entrapment efficiency 
of niosomal formulations was analysed in order to 
characterize stability profile.
In vitro release studies
A dialysis method was adopted for determination 
of the release profile of niosomal formulations (F1-F5). 
TABLE I - Composition of different niosomal formulations
Formulation 
Code
Surfactant 
(mg)
Cholesterol 
(mg)
Molar ratio 
(Surfactant: 
CHO)
Amount of drug 
(mg)
No of µmoles 
of drug
Equivalent no. 
of µmol of lipid 
contents
F1 86.2 77.33 5:5 15 40 400
F2 103.44 61.86 6:4 15 40 400
F3 120.68 46.98 7:3 15 40 400
F4 137.92 30.93 8:2 15 40 400
F5 155.16 15.46 9:1 15 40 400
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Each formulation (1 ml) was added to a dialysis bag, 
clamped and placed in a beaker containing 200 mL of 
PBS maintained at pH 7.4 and 37 oC ± 2 ºC, which acted 
as the receptor compartment, and continuous stirring was 
by a magnetic stirrer at 50 rpm. Samples were taken at 
various time-points for a period of 12 hours and assayed 
at 258.50 nm.
Release kinetic behaviour
The release pattern of diacerein from the niosomal 
formulations (F1-F5) was evaluated by applying different 
kinetic models to the observed release data to find the 
release mechanism. The following models were applied to 
the release data in order to assess the release mechanism 
from niosomes. The kinetic models (Dash et al., 2010) are 
given in equation 2, 3, 4 and 5.
 Zero order Qt = Q0 + K0 (2)
where Qt is the amount of drug released in time t, Q0 is 
the initial amount of the drug in the solution, and Ko is the 
zero-order release constant.
 Ktlog logCo
2.303
FirstOrder C = −  (3)
where Co is the initial drug concentration, t is time, and K 
is the first-order release constant. 
 Higuchi model Q = KH . t1/2  (4)
where Q is the amount of drug released in time t, and KH 
is the Higuchi dissolution constant.
Moreover, in order to determine the release 
mechanism, the Korsemeyer–Peppas model was applied 
to all formulations:
 Korsemeyer–Peppas Model nt
M
Kt
M
∞
=  (5)
where Mt/M∞ is the amount of drug released at time t, K 
is the release rate constant, and n is the release exponent. 
The n value is used to characterize the different release 
mechanisms.
Statistical analysis
To compare the mean values of vesicle size and 
entrapment efficiencies of prepared niosomes and to assess 
statistical significance, a one-way analysis of variance 
(ANOVA) was performed at 95% confidence interval 
using SPSS 20.0.
RESULTS AND DISCUSSION
Formation of niosomes
The reverse-phase evaporation technique was 
found to be optimal for designing niosomes of diacerein. 
Formulations were prepared containing  a total lipid 
mixture of 400 μmol in the order of increasing surfactant 
and decreasing the cholesterol concentration. The 
surfactant and cholesterol were dissolved in a mixture 
of chloroform and ethanol. This organic solution was 
evaporated and mixed with the drug solution following 
sonication. The emulsion was again evaporated to remove 
traces of the organic solvent and hydration was continued 
at 60 oC.
Due to its inherent characteristics, Span 60 was 
employed in this study. It is solid at room temperature, has 
a higher phase-transition temperature (53-57 oC) and an 
HLB value of 4.7. Moreover, it can form vesicles with or 
without cholesterol (Abdelkader et al., 2010). Surfactants 
with higher solubility and HLB are not able to organize 
into vesicles. Therefore, niosomes generally do not 
develop between HLB values of 14 and 17 (Girigoswami, 
Das, De, 2006). Cholesterol has been incorporated into 
formulations as a vesicle stabilizer and it also abolishes 
the gel-liquid transition of the niosomes making these 
less leaky. The finding of this study indicated that all 
ratios of Span 60 and cholesterol were able to develop 
niosomes due to the lipophilic nature of the Span 60 and 
higher efficiency of encapsulating hydrophobic drugs like 
diacerein.
Size and polydispersivity index
The size of the vesicles was found to be in the range 
of 0.5 μm to 1 μm (Table II). The comparatively small size 
of the niosomes is due to the low HLB value of Span 60 
used in the present study. The size of niosomes increases 
with increasing values of HLB (Pardakhty, Varshosaz, 
Rouholamini, 2007). The smaller size of niosomes can be 
explained on the basis of the low HLB value of Span 60, 
which results in low surface free energy, which leads to 
relatively less uptake of water in the core, and hence to 
smaller niosomes (Yoshioka, Sternberg, Florence, 1994).
The size of the vesicles was affected significantly 
(ANOVA, p<0.05) by altering the surfactant to cholesterol 
level in the formulations. These findings are in accordance 
with the results of niosomal encapsulation of oestradiol 
and mannitol (Essa, 2010). The size distribution of the 
formulations could be observed from the PDI, as shown 
in Table II, which indicates that all formulations (F1-F5) 
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are multidispersed systems. Among all five formulations, 
F3 showed the lowest value of PDI (0.409), which also 
favours the F3 formulation to be the more optimized.
Scanning electron microscopy
The SEM image of the selected formulation (F3) 
revealed the spherical shape of niosomes (Figure 1).
The shape of vesicles is predicted on the basis of the 
critical packing parameter (CPP), which is calculated from 
the area of the hydrophilic head group and the length of 
the alkyl chain of the surfactant by the following formula:
 CPP = ʋ /lc.α0 (6)
where ʋ is the lipophilic group volume, lc is the critical 
hydrophobic group length, and α0 is the area of the 
hydrophilic head group. Span 60 has a CPP value in the 
range of 0.5 to 1 and can give rise to niosomes (Uchegbu, 
Vyas, 1998). The spherical shape of the niosomes 
obtained in our study is in agreement with previous 
reports of entrapping opioid antagonist naltrexone by 
sorbitan monostearate (Abdelkader et al., 2012) and also 
entrapment of calcein in the same surfactant (Manosroi 
et al., 2003).
Drug entrapment studies
The ultracentrifugation method was found to be 
suitable for the determination of entrapment efficiency of 
niosomal formulations (F1-F5) as shown in Table III. The 
amount of entrapped drug was obtained by subtracting 
the amount of unentrapped drug from the total drug 
incorporated.
The entrapment efficiency was affected mainly 
by the molar concentration of cholesterol because the 
total molar concentration of the lipid content was kept 
constant (Table I) throughout the experiments. Previous 
studies have reached contrasting conclusions about the 
effect of the concentration of cholesterol on entrapment 
efficiency. Some reports describe that there was no effect 
of cholesterol concentration on niosomes entrapment 
efficiency (Uchegbu et al., 1995), while other studies 
show that entrapment efficiency increases with increasing 
cholesterol concentration from 0% to 50% mol/mol 
(Yoshioka, Sternberg, Florence, 1994) and another report 
showed limited enhancement of entrapment efficiency up 
to 30% mol/mol (Moazeni et al., 2010).
In our studies, entrapment efficiency was enhanced 
up to 30% mol/mol concentration of cholesterol. In 
formulations F1 and F2, entrapment efficiency was lower 
than in formulation F3, which might be ascribed to the 
fact that higher concentrations of cholesterol may cause 
disruption of the vesicles leading to leakage of drug from 
TABLE II - Average size and polydispersivity index of the 
niosomal formulations
Formulation Code Size a (μm) Polydispersivity 
Index
F1 1010×10-3 ± 0.142 0.476 ± 0.04
F2 987.1×10-3 ± 0.260 0.504 ± 0.14
F3 965.7×10-3 ± 0.119 0.409 ± 0.17
F4 835.9×10-3 ± 0.188 0.632 ± 0.05
F5 608.4×10-3 ± 0.312 0.781 ± 0.21
Data are means ±SD; p<0.05. a Size of niosomes was significantly 
different from each other according to the post-hoc test. 
FIGURE 1 - SEM image of optimized formulation F3.
TABLE III - Average entrapment efficiency of the niosomal 
formulations
Formulation 
Code
Surfactant:cholesterol 
ratio (μmolar ratio)
% Entrapment 
efficiencyb
F1 5:5 47.15 ± 0.46
F2 6:4 59.65 ± 0.51
F3 7:3 79.80 ± 0.35
F4 8:2 68.54 ± 0.39
F5 9:1 61.47 ± 0.44
Data are means ± SD; p<0.05. b Entrapment efficiency of all 
niosomal formulations was significantly different from each 
other according to the post-hoc test.
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the microenvironment of the vesicles, thus leading to 
comparatively low entrapment efficiency (Abdelkader 
et al., 2010). Formulation F3 had the highest entrapment 
efficiency (79.80%) among all the formulations as it 
contained the optimized concentration of cholesterol. 
Formulations F4 and F5 had lower entrapment efficiency 
than F3, which might be correlated with the lower amounts 
of cholesterol as compared to F3 (Table III). Statistical 
analysis of the data given in Table III demonstrated 
that percentage entrapment efficiency was significantly 
dependent upon the surfactant to cholesterol level in the 
formulations (ANOVA; p<0.05).
Stability of niosomes
The encapsulation efficiency of diacerein in the 
vesicles was determined at the end of each month. There 
was no significant change in entrapment efficiency for 
diacerein at two different temperatures after 3 months 
(Table IV). Therefore, niosomes may be an effective 
formulation to protect from drug leakage.
FTIR studies
The spectra of individual components and 
formulations of diacerein were recorded and provided 
in Figure 2. The FTIR spectrum of diacerein showed the 
principal peaks of diacerein at 1764.56 cm-1 (C=O, ester), 
1677 cm-1 (C=O stretch COOH), 1188.89 cm-1 (C—O 
stretch, ester), 760.43 cm-1 (m-substituted benzene) and 
703.02 cm-1 (benzene). Such peaks of diacerein have also 
been reported elsewhere (Silverstein, Webster, Kiemle, 
2005), which shows the purity of the diacerein sample 
and its free nature without any type of pharmacophore. 
In the spectrum of the Span 60, there were peaks of the 
hydroxyl group at 3390.20 cm-1, strong aromatic –CH3 
group 2916.75 cm-1 and the strong C=O ester bond at 
1734.63 cm-1 (Li et al., 2008). Cholesterol showed peaks 
of the hydroxyl group at 3429.82 cm-1, strong aromatic 
stretching of CH=CH at 2931.41 cm-1, and the strong C=O 
bond of carboxylic acid at 1770.20 cm-1 (Reis, Winter, 
Zerda, 1996).
The FTIR spectrum of the selected niosomal 
formulation (F3) demonstrated a slight shifting of the 
peaks and peaks were found to be remarkably diffused 
(Figure 2). No formation of any new peak was observed 
indicating that no chemical interaction occurred, and 
further smoothening of peaks depicted the strong physical 
interaction that led to the formation of niosomes. 
TABLE IV - Stability of diacerein niosomes at different temperatures
Month
Temperature 4-8 ºC Temperature 25 ºC ± 2 ºC
% Entrapment Efficiency % Entrapment Efficiency
F1 F2 F3 F4 F5 F1 F2 F3 F4 F5
0 47.1 59.65 79.80 68.54 62.47 47.1 59.65 79.80 68.54 62.47
1 46.98 59.33 79.75 68.42 62.35 46.82 59.21 79.61 68.41 62.29
2 46.70 59.12 79.35 68.23 62.08 46.60 59.05 79.19 68.11 61.95
3 46.45 58.93 78.87 68.15 61.70 45.97 58.80 78.73 67.98 61.52
FIGURE 2 - FTIR Spectra of (A) diacerein, (B) sorbitan 
monostearate, (C) cholesterol and (D) niosomal formulation F3.
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Release studies of niosomal formulations
An overall sustained release behaviour was observed 
with all formulations (F1-F5) as shown in Figure 3.The 
selected formulation (F3) expressed more prolonged 
release and only ~55% of the drug was released in the 
12-hour study design. The reason for this more retarded 
release from F3 was due to the optimum concentration 
of cholesterol in its vicinity, which provided the optimal 
strength and fluidity to the niosomes in a more efficient 
way.
Another reason is the reduction of the efflux of 
diacerein from niosomal vesicles by stabilizing the 
vesicular membrane and making it more rigid and less 
leaky (Demel, Dekruyff, 1976; Korchowiec et al., 2006). 
A similar phenomenon was observed with niosome-
entrapped rifampicin, where the cholesterol was found to 
retard the release of the drug (Jain, Vyas, 1995). The slow 
release of drug from niosomes is also attributed to the use 
of Span 60, which has a slower rate of release than Span 
20, 80 and 85, which in turn is due to the reason that Span 
60 molecules remain in an ordered gel state, but other 
Spans are in a disordered liquid crystalline state (Attia et 
al., 2007).
Release kinetic behaviour
The regression coefficient (r2) values were 
approximated to follow zero-order release. Formulation 
F3 was the more optimized as it showed r2=0.9834. 
All equations including zero order, Higuchi model 
and Korsemeyer-Peppas equations, exhibited good 
linearity for the optimized selected formulation (F3). The 
Korsemeyer-Peppas model was applied to all formulations 
data and the n value was calculated. The value of n for 
all formulations suggests non-fickian (anomalous) - i.e. 
coupling of both diffusion and erosion - mechanisms 
(Costa, Sousalobo, 2001). Table V gives the values of 
the rate constants and regression correlations using rate 
equations for the release of diacerein from niosomes. The 
overall results revealed that the zero-order r2 values for all 
formulations were higher than the first-order values, which 
suggests that niosomal formulations (F1-F5) can release the 
drug in sustained manner.
CONCLUSION
Niosomal formulations of Span 60 and cholesterol 
were successfully prepared by a reverse-phase evaporation 
method. Optimizing the concentration of cholesterol to an 
optimum level (F3) increased the entrapment efficiency 
and sustained the release of diacerein from the niosomes. 
The formulation (F3, 7:3) showed maximum encapsulation 
efficiency (79.80%) and a prolonged release profile 
(55%) in 12 hours. The prepared niosomes can be used as 
potential carrier for the controlled release and enhanced 
availability of the diacerein at the site of absorption.
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